Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer.

Matthias MollAndreas RennerChristian KirisitsChristopher PaschenAlexandru ZaharieGregor Goldner

Published in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2021)

Favorable intermediate-risk prostate cancer patients can be treated either by external beam radiotherapy (74/78 Gy) or permanent interstitial seed brachytherapy.

Keyphrases

prostate cancer
radiation therapy
high dose
locally advanced
radical prostatectomy
early stage
squamous cell carcinoma
rectal cancer
low dose
electron microscopy
breast cancer risk